$SVA
Sinovac Biotech Ltd
Nasdaq · Healthcare · Pharmaceutical Preparations · Beijing
SVA chart
What traders are saying about $SVA
Latest postsSinovac Biotech Ltd news
- View / What the world should learn from China’s health innovation
Semafor ·
- China’s Biotechnology Expansion Spreads Across Latin America
Diálogo Americas ·
- Sinovac Biotech, Ltd. Estimates – NASDAQ:SVA
TradingView ·
- SINOVAC Reports Unaudited First Half of 2026 Financial Results
Yahoo Finance ·
- SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend
Yahoo Finance ·
- SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements
Yahoo Finance ·
- SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
Yahoo Finance ·
- SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report
Yahoo Finance ·
- OrbiMed Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
fool.com ·
- Coxsackievirus Infections Market Research Report 2025-2035: High Burden of Pediatric and Neonatal Infections, Link to Type 1 Diabetes Risk, Advances in Vaccine Development Driving Expansion
Yahoo Finance ·
- Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
Yahoo Finance ·
Sinovac Biotech Ltd key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $386.0M | $361.4M | $470.2M | $1.47B |
| Net income | – | – | -$13.5M | $14.5M |
| Diluted EPS | $-0.83 | $1.27 | $-0.19 | $0.20 |
| Total assets (year end) | $8.54B | $12.34B | $13.61B | $14.03B |
| Cash and equivalents (year end) | $488.2M | $335.3M | $1.12B | $3.88B |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 6-K6-K
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 20-F20-F
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 20-F20-F
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
- 6-KREPORT OF FOREIGN PRIVATE ISSUER
About Sinovac Biotech Ltd
- Ticker
- SVA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Beijing
- Incorporated in
- Antigua and Barbuda
- Fiscal year end
- December 31
- SEC CIK
- 1084201
- Former names
- NET FORCE SYSTEMS INC
Frequently asked questions
What exchange is Sinovac Biotech Ltd listed on?
Sinovac Biotech Ltd trades on the Nasdaq under the ticker symbol SVA.
What industry is Sinovac Biotech Ltd in?
Sinovac Biotech Ltd is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Sinovac Biotech Ltd headquartered?
Sinovac Biotech Ltd's business address on file with the SEC is in Beijing.
When does Sinovac Biotech Ltd's fiscal year end?
Sinovac Biotech Ltd's fiscal year ends on December 31.
How much revenue did Sinovac Biotech Ltd report?
Sinovac Biotech Ltd reported $386.0M in revenue for calendar year 2025, according to its SEC filings.